Abstract: A myoregulin inhibitor such as an antisense oligonucleotide against myoregulin or an anti-myoregulin antibody is used as an active ingredient of a prophylactic or therapeutic agent for a muscle disease such as muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, disused muscular atrophy, and sarcopenia.

Abstract: A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 ?g/mL to 10 ?g/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value.

Abstract: Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and a second drug (for example, a drug comprising a multivalent cation such as calcium, iron, magnesium, lanthanum, aluminum, and the like; a statin drug; sulfasalazine; or furosemide), to a subject.

Abstract: An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

Abstract: A medicament for treatment or prevention of porphyria, comprising 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or a pharmaceutically acceptable salt or cocrystal thereof as an active ingredient, wherein the dose of the 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or the pharmaceutically acceptable salt or cocrystal thereof is 50 to 500 mg/day.

Abstract: A medicament for treating or preventing a condition that is treatable or preventable by promotion of melanin production, such as photodermatoses (excluding porphyria), hypopigmentary disease (excluding vitiligo vulgaris), adverse effects of phototherapy, or gray hair, said medicament comprising a compound represented by general formula [I], or a pharmaceutically acceptable salt or cocrystal thereof, as an active ingredient.

Abstract: A modified oligonucleotide having an activity of inhibiting Ataxin 3 expression and having any one of the following nucleobase sequences or a nucleobase sequence of 17 contiguous bases contained in the nucleobase sequences: (SEQ?ID?NO:?239) (1) TCGGGTAAGTAGATTTTC, (SEQ?ID?NO:?240) (2) GAAGTATCTGTAGGCCTA, (SEQ?ID?NO:?241) (3) GGACTGTATAGGAGATTA, (SEQ?ID?NO:?242) (4) GGTTATAGGATGCAGGTA, (SEQ?ID?NO:?243) (5) AGGTTATAGGATGCAGGT, (SEQ?ID?NO:?244) (6) GAAGCTAAGTAGGTGACT, (SEQ?ID?NO:?245) (7) TGAAGCTAAGTAGGTGAC, (SEQ?ID?NO:?246) (8) CCTAGTCACTTTGATAGA, (SEQ?ID?NO:?247) (9) GGAACATCTTGAGTAGGT, (SEQ?ID?NO:?248) (10) GGTGTTCAGGGTAGATGT, (SEQ?ID?NO:?249) (11) GGATACTCTGCCCTGTTC, (SEQ?ID?NO:?250) (12) GGTGTCAAACGTGTGGTT, (SEQ?ID?

Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.

Abstract: A prophylactic or therapeutic agent for an aneurysm comprising a miR-33b inhibiting substance, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.

Abstract: The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.

Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.

Abstract: A pharmaceutical composition of 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a salt thereof is provided. The composition is superior in storage stability and can suppress production of related substances. An excipient selected from dibasic calcium phosphate, calcium dihydrogen phosphate, dibasic sodium phosphate, and sodium dihydrogen phosphate is used.

Abstract: This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating dementia selected from diabetic dementia and vascular dementia.

Abstract: The present invention provides a mutant RSV F protein having a mutation, wherein the mutation is a substitution of a leucine corresponding to a leucine at position 141 of an amino acid sequence of SEQ ID NO: 1 or a leucine corresponding to a leucine at position 142 with a cysteine, and a substitution of a leucine corresponding to a leucine at position 373 with a cysteine, and a disulfide bond is formed between the cysteines. Further provided is a mutant RSV F protein having a mutation, wherein the mutation is a substitution of a glutamic acid corresponding to a glutamic acid at position 60 of the amino acid sequence of SEQ ID NO: 1 with a non-acidic amino acid.

Abstract: This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating diabetic autonomic neuropathy.

Abstract: The present invention aims to provide a therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia. A therapeutic agent for a disease selected from myalgic encephalomyelitis/chronic fatigue syndrome, and fibromyalgia. containing 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Abstract: An ALS treatment method includes administering to an ALS patient an inhibitor for a target A or a promoter for a target B. The target A is one or more genes selected from the genes in Table 1-1 or a protein encoded by the gene, and the inhibitor for the target A is a substance that inhibits expression of the gene, or a substance that inhibits a function of the protein encoded by the gene. The target B is one or more genes selected from the genes in Table 1-2 or a protein encoded by the gene, and the promoter for the target B is a substance that promotes the expression of the gene, or a substance that promotes a function of the protein encoded by the gene.

Abstract: The present invention aims to provide a prophylactic agent or therapeutic agent for human non-alcoholic steatohepatitis (NASH), the agent being capable of (i) reducing body weight, (ii) changing the amount of HA, the amount of PIIINP, and the amount of TIMP-1, in serum, and changing the amount of sVCAM-1 in plasma, or (iii) reducing liver stiffness. The object is achieved by a prophylactic agent or therapeutic agent for human non-alcoholic steatohepatitis (NASH), including: the 1,4-benzoxazine compound represented by Formula (I) or a pharmaceutically acceptable salt thereof as an effective component; and a pharmaceutically acceptable carrier; the agent being capable of (i) reducing body weight, (ii) changing the amount of HA, the amount of PIIINP, and the amount of TIMP-1, in serum, and changing the amount of sVCAM-1 in plasma, or (iii) reducing liver stiffness.

Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor. A compound represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.